Evidence map›Paper›PMID 32723309›Full record

SynthesisBMC pregnancy and childbirth2020

Burden of hepatitis E virus infection in pregnancy and maternofoetal outcomes: a systematic review and meta-analysis.

Jean Joel Bigna, Abdou Fatawou Modiyinji, Jobert Richie Nansseu, Marie A Amougou, Moise Nola, Sébastien Kenmoe, Elvis Temfack, Richard Njouom

Registry-linked trialAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in BMC pregnancy and childbirth, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05808166 (A Phase II, Randomized, Observer-blinded, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women Between Gestational Age 14-34 Weeks and Non-Pregnant Women of 16-45 Years Old.), which is not on this map. Cited by 35 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05808166 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase II, Randomized, Observer-blinded, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women Between Gestational Age 14-34 Weeks and Non-Pregnant Women of 16-45 Years Old.

TypeinterventionalSponsorInternational Vaccine InstituteRan2024 to 2026Enrolled2,358ConditionsHepatitis E InfectionArmsHecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli))., Isotonic Sodium Chloride injection
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Immunogenicity and safety of co-administeredFrontiers in immunology · 2026
    Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Article
  12. Preexisting Liver Disease and Pregnancy: Optimizing Care to Optimize Outcomes.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Role of viral hepatitis in pregnancy and its triggering mechanism.Journal of translational internal medicine · 2024
    Article
  20. Peripartum Infections: A Position Statement of the Indian Society of Critical Care Medicine.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jean Joel BignaDepartment of Epidemiology and Public Health, Centre Pasteur of Cameroon, P.O. Box 1274, Yaoundé, Cameroon. bignarimjj@yahoo.fr.ORCID http://orcid.org/0000-0001-8018-6279
Abdou Fatawou ModiyinjiDepartment of Virology, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Jobert Richie NansseuDepartment for the Control of Disease, Epidemics and Pandemics, Ministry of Public Health, Yaoundé, Cameroon.
Marie A AmougouDepartment of Virology, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Moise NolaDepartment of Animals Biology and Physiology, Faculty of Sciences, University of Yaoundé I, Yaoundé, Cameroon.
Sébastien KenmoeDepartment of Virology, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Elvis TemfackDepartment of Internal Medicine, Douala General Hospital, Douala, Cameroon.
Richard NjouomDepartment of Virology, Centre Pasteur of Cameroon, Yaoundé, Cameroon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is still a dearth of knowledge on the burden of HEV infection in the global population of pregnant women. Therefore, we conducted a systematic review and meta-analysis to estimate the global burden of HEV infection in pregnancy.

methodsWe searched PubMed, Embase, Web of Knowledge, and Global Index Medicus to identify articles published until January 26, 2020. We considered cross-sectional, case-control, and cohort studies reporting the immunoglobulins M HEV seroprevalence in asymptomatic and symptomatic (jaundice or elevated transaminases) pregnant women or investigating the association between HEV infection and maternofoetal outcomes. We used a random-effects model to pool studies. This review was registered with PROSPERO, CRD42018093820.

resultsFor HEV prevalence estimates, we included 52 studies (11,663 pregnant women). The seroprevalence was 3.5% (95% confidence interval: 1.4-6.4) in asymptomatic women (most of whom from high endemic areas). The prevalence in symptomatic women was 49.6% (42.6-56.7) with data only from HEV high endemic countries. In the multivariable meta-regression model, the prevalence was higher in symptomatic women compared to asymptomatic (adjusted prevalence odds ratio [aPOR]: 1.76; 95%CI: 1.61-1.91) and decreased with increasing year of publication (by 10-year) (aPOR: 0.90; 95%CI: 0.84-0.96). The proportion of HEV vertical transmission was 36.9% (13.3-64.2). Risk of bias was low, moderate and high respectively in 12 (23%), 37 (70%), and 4 studies (7%) addressing HEV prevalence estimation. HEV infection was associated with maternal deaths (pooled OR 7.17; 3.32-15.47), low birth weight (OR: 3.23; 1.71-6.10), small for gestational age (OR: 3.63; 1.25-10.49), preterm < 32 weeks (OR: 4.18; 1.23-14.20), and preterm < 37 weeks (OR: 3.45; 2.32-5.13), stillbirth (OR: 2.61; 1.64-4.14), intrauterine deaths (OR: 3.07; 2.13-4.43), and not with miscarriage (OR: 1.74; 0.77-3.90). All studies which assessed the association between HEV infection and maternofoetal outcomes had a moderate risk of bias.

conclusionsFindings from this study are suggestive of a high burden of HEV infection in pregnancy in high endemic countries, its association with poor maternofoetal outcomes, and a high rate of vertical transmission. This study supports the need for specific strategies to prevent exposure of pregnant women to HEV infection, especially in high endemic areas.

Indexed as

AdultCase-Control StudiesCohort StudiesCross-Sectional StudiesFemaleHepatitis EHepatitis E virusHumansInfant, Low Birth WeightInfant, NewbornInfectious Disease Transmission, VerticalPregnancyPregnancy Complications, InfectiousPregnancy OutcomeSeroepidemiologic StudiesHepatitis EIntrauterine deathsLow birth weightMaternal deathsMiscarriagePregnancyPretermSmall for gestational ageVertical transmissionWomen health

Identifiers

PMID32723309
PMCPMC7388479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.